Residency · Omaha, NE
Sponsored by University of Nebraska Medical Center College of Medicine
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
The New England journal of medicine · 2021 · 8,425 citations · Brandon Essink
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
The New England journal of medicine · 2022 · 518 citations · Brandon Essink
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
The New England journal of medicine · 2021 · 495 citations · Brandon Essink
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022 · 134 citations · Brandon Essink
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
The Lancet. Infectious diseases · 2023 · 123 citations · Brandon Essink
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
The Journal of infectious diseases · 2023 · 107 citations ·
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.
Human vaccines & immunotherapeutics · 2025 · 29 citations · Brandon Essink
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.
The Journal of infectious diseases · 2024 · 51 citations · Brandon Essink